ERBB2 and breast carcinoma: However, for quantitative HER2 methods to have clinical utility, they would need to be validated in trials studying whether they are predictive of benefit from HER2 targeted therapies in patients with HER2-positive, HER2-low, and HER2-ultralow breast cancer (24).